PRQR News and Press, ProQR Therapeutics N.V. From 12/22/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/Nixx Photography Chinese electric vehicle (EV) stocks are a chief concern among investors today as these shares see mixed trading. Investors continue to watch Chinese stocks like a hawk for sign...

Dutch biotech ProQR Therapeutics N.V. ( NASDAQ: PRQR ) added ~35% pre-market Thursday in reaction to an agreement with Eli Lilly ( NYSE: LLY ) to expand the partnership for RNA-editing-based genetic medicines. The deal, first announced in September 2021, was designed to ta...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that ProQR management will host an investor conference call and webcast to disc...

Lilly and ProQR to Expand RNA Editing Collaboration PR Newswire New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR's Axiomer technology INDIANAPOLIS and LEIDEN, Netherlands and CAMBRID...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleoti...

ProQR press release ( NASDAQ: PRQR ): Q3 GAAP EPS of -€0.34. Revenue of €0.96M (+10.3% Y/Y). For further details see: ProQR GAAP EPS of -€0.34, revenue of €0.96M

Development of Axiomer ® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023 Management Team appointments and planned additions t...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- LEIDEN, Netherlands & CAMBRIDGE, Mass., November 3, 2022 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RN...

Raymond James has upgraded ProQR Therapeutics N.V. ( NASDAQ: PRQR ) to Outperform from Market Perform after the Dutch biotech announced on Thursday a decision to focus on its Axiomer RNA- editing technology platform exclusively. The upgrade is “based on high convi...

Dutch biotech ProQR Therapeutics N.V. ( NASDAQ: PRQR ) announced on Thursday that the European Medicines Agency (EMA) recommended an additional pivotal clinical trial before submitting a marketing application for the company’s lead candidate sepofarsen. An investiga...